Related Experiment Video
Updated: Mar 3, 2026
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
MicroRNAs: pleiotropic players in congenital heart disease and regeneration
Sarah C Hoelscher1, Stefanie A Doppler1, Martina Dreßen1
1Division of Experimental Surgery, Department of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, Germany.
Insights
MicroRNAs (miRs) play a key role in congenital heart disease (CHD) development and outcomes. Targeting miRs offers promising therapeutic strategies for regenerative medicine in infants with CHD.
Area of Science:
- Cardiovascular Biology
- Developmental Biology
- Molecular Medicine
Background:
- Congenital heart disease (CHD) is a primary cause of infant mortality, with significant challenges remaining despite surgical advancements.
- MicroRNAs (miRs) are crucial regulators of cardiac development and are implicated in pathological processes like fibrosis, hypertrophy, and impaired angiogenesis.
- Dysregulated miRs are hypothesized to contribute to CHD etiology and adverse clinical outcomes in affected infants.
Purpose of the Study:
- To review the function of miRs in cardiac development and disease.
- To elucidate the specific roles of miRs in various congenital heart defects, including hypoplastic left heart syndrome (HLHS), tetralogy of Fallot (TOF), ventricular septal defects (VSDs), and Holt-Oram syndrome (HOS).
- To explore the therapeutic potential of miRs and their targets in regenerative medicine for CHD.
Main Methods:
- Literature review of miR function in cardiac development and congenital heart diseases.
- Analysis of existing research on miR dysregulation in specific CHDs.
- Synthesis of current knowledge linking miRs to pathological cardiac processes relevant to CHD.
Main Results:
- miRs are integral to normal cardiac development.
- Aberrant miR expression is associated with the pathogenesis and progression of various CHDs.
- Specific miRs and their targets are identified as potential mediators of disease pathways in CHD.
Conclusions:
- MicroRNAs represent a significant area of investigation for understanding CHD.
- miRs hold considerable promise as therapeutic targets for regenerative strategies in congenital heart disease.
- Targeting miRs could lead to novel treatments to improve clinical outcomes for infants with CHD.
Abstract:
Congenital heart disease (CHD) is the leading cause of infant death, affecting approximately 4-14 live births per 1,000. Although surgical techniques and interventions have improved significantly, a large number of infants still face poor clinical outcomes. MicroRNAs (miRs) are known to coordinately regulate cardiac development and stimulate pathological processes in the heart, including fibrosis or hypertrophy and impair angiogenesis. Dysregulation of these regulators could therefore contribute (I) to the initial development of CHD and (II) at least partially to the observed clinical outcomes of many CHD patients by stimulating the aforementioned pathways. Thus, miRs may exhibit great potential as therapeutic targets in regenerative medicine. In this review we provide an overview of miR function and elucidate their role in selected CHDs, including hypoplastic left heart syndrome (HLHS), tetralogy of Fallot (TOF), ventricular septal defects (VSDs) and Holt-Oram syndrome (HOS). We then bridge this knowledge to the potential usefulness of miRs and/or their targets in therapeutic strategies for regenerative purposes in CHDs.
